AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 09:05:01 05/07/2024 pm IST			5-day change	1st Jan Change
12,056 ^GBX	-0.41%		-2.43%	+13.74%

05/07	AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	MT
05/07	AstraZeneca: cancer treatment approved by the EU	CF

ASTRAZENECA : Goldman Sachs maintains a Buy rating

July 04, 2024 at 05:23 pm IST

In a research note published by Rajan Sharma, Goldman Sachs advises its customers to buy the stock. The target price is set at 15131 versus 15200 GBX.

Latest news about AstraZeneca PLC

AstraZeneca's Tagrisso Approved by EU as First-Line Treatment for Non-Small Cell Lung Cancer	05/07	MT
AstraZeneca: cancer treatment approved by the EU	05/07	CF
AstraZeneca drug Tagrisso gets EU approval for cancer form	05/07	AN
EU Approves AstraZeneca's Tagrisso Combo as Non-small Cell Lung Cancer Treatment	05/07	MT
ASTRAZENECA : Goldman Sachs maintains a Buy rating	04/07	ZD
ASTRAZENECA : Buy rating from Berenberg	03/07	ZD
Aptamer shares jump as inks agreement with AstraZeneca	03/07	AN
Aptamer Group plc Announces New Agreement with AstraZeneca to Evaluate the Optimer Fibrotic Liver Delivery Vehicles for the Targeted Delivery of SiRNA	03/07	CI
ASTRAZENECA : Jefferies reaffirms its Neutral rating	02/07	ZD
Deutsche Bank cuts Quilter, ups Polar Capital	02/07	AN
European Equities Close Higher in Monday Trading; Eurozone Manufacturing Contraction Widens in June	01/07	MT
UK Stocks Flat; Manufacturing Sector Remains in Expansion Zone	01/07	MT
AstraZeneca's Potential Covid-19 Prevention Drug Gets EU Accelerated Assessment	01/07	MT
AstraZeneca's Imfinzi, Lynparza Combination Recommended for Approval in Europe as Endometrial Cancer Treatment	01/07	MT
AstraZeneca applies to the EMA for a Covid antibody	01/07	CF
AstraZeneca: CHMP recommends Imfinzi and Lynparza	01/07	CF
Stocks called higher ahead of Thursday's election	01/07	AN
AstraZeneca's Combination Formulation for Endometrial Cancer Gains Support for EU Application	01/07	MT
AstraZeneca's Application for COVID-19 Prevention Drug Wins Accelerated Review in EU	01/07	MT
AstraZeneca's COVID prevention drug application gets EU fast-track assessment	01/07	RE
AstraZeneca Plc's Lynparza & Imfinzi Announces Positive CHMP in Endometrial	01/07	CI
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06	RE
European Equities Close Lower in Wednesday Trading	26/06	MT
ASTRAZENECA : Deutsche Bank sticks Neutral	26/06	ZD
AstraZeneca Says Tagrisso With Chemotherapy Approved in China	26/06	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : Strong Q1 raises hopes of a guidance upgrade

April 25, 2024 at 09:32 pm IST

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

154.4 USD

Average target price

174.6 USD

Spread / Average Target

+13.10%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+13.74%	24TCr
ELI LILLY AND COMPANY	+56.89%	82TCr
NOVO NORDISK A/S	+39.52%	63TCr
JOHNSON & JOHNSON	-6.55%	35TCr
MERCK & CO., INC.	+15.99%	32TCr
ABBVIE INC.	+7.92%	30TCr
NOVARTIS AG	+13.83%	22TCr
ROCHE HOLDING AG	-0.49%	22TCr
AMGEN INC.	+7.94%	17TCr
PFIZER, INC.	-2.57%	16TCr

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Goldman Sachs maintains a Buy rating

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals